Starpharma Holdings Limited

Starpharma Holdings Limitedverified

SPHRY

Price:

$4.6

Market Cap:

$294.65M

Starpharma Holdings Limited is an Australian biopharmaceutical company dedicated to advancing and marketing its proprietary dendrimer technology across global pharmaceutical, life-science, and other sectors. Among its current offerings are VivaGel, a non-antibiotic treatment designed for the management and prevention of bacterial vaginosis, alongside the antiviral VivaGel condom and VIRALEZE antiviral nasal spray. Furthermore, the company's extensive pipeline heavily features its DEP dendrimer drug delivery system, which includes several oncology candidates such as DEP docetaxel, DEP cabazitaxel, and DEP irinotecan, all currently undergoing Phase II clinical trials for various cancers. Addit...[Read more]

Industry

Biotechnology

IPO Date

2007-05-04

Stock Exchange

OTC

Ticker

SPHRY

The PE Ratio as of June 2026 (TTM) for Starpharma Holdings Limited (SPHRY) is -76.67

According to Starpharma Holdings Limited’s latest financial reports and current stock price. The company's current PE Ratio is -76.67. This represents a change of -1484.79% compared to the average of 5.54 of the last 4 quarters.

Starpharma Holdings Limited (SPHRY) Historical PE Ratio (quarterly & annually)

How has SPHRY PE Ratio performed in the past?

The mean historical PE Ratio of Starpharma Holdings Limited over the last ten years is -19.72. The current -76.67 PE Ratio has changed 38.77% with respect to the historical average. Over the past ten years (40 quarters), SPHRY's PE Ratio was at its highest in in the December 2025 quarter at 27.58. The PE Ratio was at its lowest in in the December 2012 quarter at -50.01.

Quarterly (TTM)
Annual

Average

-19.72

Median

-18.08

Minimum

-42.11

Maximum

-3.67

Starpharma Holdings Limited (SPHRY) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Starpharma Holdings Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 138.40%

Maximum Annual PE Ratio = -3.67

Minimum Annual Increase = -58.11%

Minimum Annual PE Ratio = -42.11

Quarterly (TTM)
Annual
YearPE RatioChange
2025-3.67-20.11%
2024-4.60-40.65%
2023-7.75-58.11%
2022-18.50-38.33%
2021-30.006.19%
2020-28.25-17.52%
2019-34.25-18.66%
2018-42.11138.40%
2017-17.6668.97%
2016-10.45-12.51%

Starpharma Holdings Limited (SPHRY) Average PE Ratio

How has SPHRY PE Ratio performed in the past?

The current PE Ratio of Starpharma Holdings Limited (SPHRY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-5.34

5-year avg

-12.91

10-year avg

-19.72

Starpharma Holdings Limited (SPHRY) PE Ratio vs. Peers

How is SPHRY’s PE Ratio compared to its peers?

Starpharma Holdings Limited’s PE Ratio is less than Imugene Limited (-0.49), less than Satellos Bioscience Inc. (-1.76), less than IXICO plc (-4.23), less than Alterity Therapeutics Limited (-8.02), less than Paradigm Biopharmaceuticals Limited (-2.06), less than Poolbeg Pharma PLC (-9.37), less than BioStem Technologies, Inc. (-3.52), less than Nicox S.A. (-13.59), less than Kintor Pharmaceutical Limited (-4.64), less than BioSyent Inc. (17.56),

Build a custom stock screener for Starpharma Holdings Limited (SPHRY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Starpharma Holdings Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Starpharma Holdings Limited (SPHRY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Starpharma Holdings Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Starpharma Holdings Limited's PE Ratio?

How is the PE Ratio calculated for Starpharma Holdings Limited (SPHRY)?

What is the highest PE Ratio for Starpharma Holdings Limited (SPHRY)?

What is the 3-year average PE Ratio for Starpharma Holdings Limited (SPHRY)?

What is the 5-year average PE Ratio for Starpharma Holdings Limited (SPHRY)?

How does the current PE Ratio for Starpharma Holdings Limited (SPHRY) compare to its historical average?